Management of Stage IV, ER/PR Positive, HER2 Negative Breast Cancer

Evaluation and Treatment Approach

The National Comprehensive Cancer Network recommends re-evaluation of tumor characteristics through biopsy of accessible metastatic lesions to confirm ER/PR and HER2 status, as receptor status can change during disease progression 1
Assessment of disease burden and distribution through appropriate imaging is essential to determine the extent of metastatic involvement, according to the National Comprehensive Cancer Network 2
Evaluation of response to previous doxorubicin therapy should guide subsequent treatment decisions, with stable disease indicating potential benefit from a different treatment approach, as reported in Annals of Oncology 3, 4

For ER/PR positive, HER2 negative metastatic breast cancer with stable disease after chemotherapy, the National Comprehensive Cancer Network recommends endocrine therapy as the preferred next step 1, 3
The National Comprehensive Cancer Network suggests considering adding a CDK4/6 inhibitor to endocrine therapy, as this combination has shown improved progression-free survival in the metastatic setting 1
Single-agent abemaciclib may be considered for patients who have progressed on prior endocrine therapy and chemotherapy, with a reported objective response rate of 19.7% and median progression-free survival of 6 months, according to the National Comprehensive Cancer Network 1

If disease progresses on endocrine therapy, consider alternative chemotherapy options, such as taxanes, which may be effective if not previously used, as reported in Annals of Oncology 4
Selection of chemotherapy should be based on previous treatments, toxicity profile, and patient's performance status, according to Annals of Oncology 3, 4

For patients with bone metastases, the National Comprehensive Cancer Network recommends adding bone-modifying agents to reduce skeletal-related events 2
Clinical trials should be considered at any point in the treatment course, especially for patients with limited standard options, as reported in Annals of Oncology 3

Evaluate response to endocrine therapy after approximately 3 months through clinical assessment, imaging, and tumor markers, as recommended in Annals of Oncology 4
Continue effective therapy until disease progression or unacceptable toxicity, according to Annals of Oncology 3